A. Gonschior

发表

Update in the pharmaceutical therapy of the irritable bowel syndrome

S. Maxion-Bergemann, F. Thielecke, F. Abel, 2004, International journal of clinical practice.

Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients.

U. Christians, A. Gonschior, M. Winkler, 1996, Clinical chemistry.

Cost-Effectiveness of Dabigatran Etexilate for the Secondary Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism in the United Kingdom

S. Wolowacz, T. Sunderland, A. Gonschior, 2013 .

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

S. Parsons, S. Al-Batran, P. Wimberger, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of the Pro-Trac tacrolimus monoclonal whole-blood enzyme-linked immunosorbent assay for monitoring of tacrolimus levels in patients after kidney, heart, and liver transplantation.

U. Christians, R. Pichlmayr, A. Gonschior, 1996, Therapeutic drug monitoring.

Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA).

U. Christians, F. Braun, A. Gonschior, 1994, British journal of clinical pharmacology.

Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability.

U. Christians, J. Kolars, P. Watkins, 1995, Drug metabolism and disposition: the biological fate of chemicals.

Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber

U. Christians, A. Lampen, W. Engelhardt, 1996, British journal of pharmacology.

Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.

S. Sorensen, A. Kansal, J. Heinrich-Nols, 2014, Clinical therapeutics.

3004 POSTER DISCUSSION Quality of Life in Patients With Malignant Ascites and Ascites Symptoms After Treatment With Catumaxomab: Results From a Multicenter Phase ll/lll Study Comparing Paracentesis Plus Catumaxomab With Paracentesis Alone

S. Parsons, M. Hennig, P. Wimberger, 2011 .

Quality of Life in Patients With Malignant Ascites and Ascites Symptoms After Treatment With Catumaxomab: Results From a Multicenter Phase II/III Study Comparing Paracentesis Plus Catumaxomab With Paracentesis Alone

S. Parsons, M. Hennig, P. Wimberger, 2011 .

Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry

U. Christians, K. Böker, R. Pichlmayr, 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

Simplified High‐Performance Liquid Chromatography‐Mass Spectrometry Assay for Measurement of Tacrolimus and Its Metabolites and Cross‐Validation with Microparticle Enzyme Immunoassay

H. Schiebel, U. Christians, A. Gonschior, 1995, Therapeutic drug monitoring.

190 EVALUATION OF THE NEW PRO-TRACR TACROLIMUS MONOCLONAL WHOLE BLOOD ELISA FOR MONITORING OF TACROLIMUS LEVELS IN PATIENTS AFTER KIDNEY, HEART AND LIVER TRANSPLANT

U. Christians, A. Gonschior, M. Winkler, 1995 .

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.

S. Parsons, S. Al-Batran, P. Wimberger, 2012 .

Application of primary hepatocyte sandwich cultures for predictive studies of drug metabolism and precarcinogen activation

K. Sewing, H. Esselmann, A. Bader, 1997 .